Research Interests
Research Summary
S. Chia’s main research interest lie in translational research and in clinical research. His translational research is primarily in breast cancer, with a focus on assessment and validation of new and novel prognostic and predictive factors. He has numerous peer reviewed grants as the lead independent PI, as well has published several peer reviewed papers as the first author in this area. His clinical research involves phase I-III clinical trials as well as population based outcomes research. Has been the lead PI for a large international phase III trial (see below) which has been published (J Clin Oncol 2008;26:1664-1670) as well as the lead PI on two investigator led phase II trials in neoadjuvant therapy of locally advanced breast cancer. He is also involved in phase I-II trials in investigational new drugs as well as in head and neck cancer.
Research Highlights
Personal
Education
University of British Columbia, Pharmacology, B.Sc.,
University of British Columbia, MD,
Affiliations
Recent Publications
•Brown LA, Irving J, Parker R, Kim H, Press JZ, Longacre TA, Chia S, Magliocco A, Makretsov N, Gilks B, Pollack J and Huntsman D. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol Oncol 2006;100:264-70.
•Cheang M, Treaba DO, Speers CH, Olivotto IA, Bajdik CD, Chia SK, Goldstein LC, Gelmon KA, Huntsman DA, Gilks CB, Nielsen TO and Gown AM. Immunohistochemical detection of estrogen receptor in breast cancer using the new rabbit monoclonal antibody SP1 predicts survival better than mouse monoclonal antibody 1D5. J Clin Oncol 2006;24:5637-5644.
•Chia S, Clemons M, Martin LA, Rodgers A, Gelmon K, Pond GR and Panasci L. Pegylated liposomal doxorubicin and trastuzumab in HER-2 over-expressing metastatic breast cancer: A multi-center phase II trial. J Clin Oncol 2006;24:2773-2778.
•Chia SK, Speers CH, D’yachkova Y, Kang A, Malfair-Taylor S, Barnett J, Coldman A, Gelmon KA, O’Reilly SE and Olivotto A. The impact of new chemotherapeutics and hormonal agents on survival in a population based cohort of women with metastatic breast cancer. Cancer 2007;110:973-979.
•Kennecke HF, Olivotto IA, Speers C, Norris B, Chia SK, Bryce C and Gelmon KA. Late risk of relapse and mortality among post-menopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol 2007;18:45-51.
•Robinson A, Speers C, Olivotto IA and Chia S. Method of detection of new contralateral primary breast cancers in younger versus older women. Clin Breast Cancer 2007;7:705-709.
•Cheang MCU, Voduc D, Bajdik C, Leung S, McKinney S, Chia S, Perou CM and Nielsen TO. Basal like breast cancer defined by five biomarkers has significant superior prognostic value than by triple negative phenotype. Clin Cancer Res 2008;14:1368-1376.
•Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson J, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M. A Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant versus Exemestane Following Prior Non-Steroidal Aromatase Inhibitor Therapy in Post-menopausal Women with Hormone Receptor Positive Advanced Breast Cancer: Results from EFECT. J Clin Oncol 2008;26:1664-1670.
•Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM, Huntsman D, Olivotto IA, Nielsen TO and Gelmon K. HER-2 Over-expression as a Prognostic Factor in a Large Tissue Microarray Series of Node Negative Breast Cancers. J Clin Oncol 2008;26:5697-5704.
•Chia S, Swain SM, Byrd DR and Mankoff DA. Locally Advanced and Inflammatory Breast Cancer. J Clin Oncol 2008;26:786-790.
•Chia S, W. Fulvestrant: Expanding the endocrine treatment options for patients with hormone receptor positive advanced breast cancer. The Breast 2008;17:S16-21.
•Crabb SJ, Cheang MCU, Leung S, Immonen T, Nielsen T, Huntsman DD, Bajdik CD and Chia SK. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Breast Cancer 2008;8:249-56.
•Kennecke H, McArthur H, Olivotto IA, Speers C, Bajdik C, Chia SK, Ellard S, Norris B, Hayes M, Barnett J, and Gelmon KA. Risk of early recurrence among postmenopausal women with estrogen receptor positive early breast cancer treated with adjuvant tamoxifen. Cancer 2008;112:1437-44.
•Rayson D, Richel D, Chia S, Jackisch C, van der Vegt S and Suter T. Anthracycline-trastuzumab regimens for HER2/neu overexpressing breast cancer: current experience and future strategies. Ann Oncol 2008;19:1530-9.
•Tang PA, Siu LL, Chen EX, Hotte SJ, Chia S, Schwarz JK, Pond GR, Johnson C, Colevas AD, Wynold TW, Vasist LS and Winquist E. Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs 2008;26:257-264.
•Tinker AV, Speers C, Barnett J, Olivotto IA and Chia S. Impact of a reduced dose intensity of adjuvant anthracycline based chemotherapy in a population based cohort of stage I-II breast cancer. ecancermedicalsciences 2008;2:62. DOI: 10.3332.
•Au H, Golmohammadi, Younis T, Verma S, Chia S, and Jacobs P. A Cost-Effectiveness Analysis of Adjuvant Docetaxel, Adriamycin, and Cyclophosphamide (TAC) for Node-Positive Breast Cancer: Modeling the Downstream Effects. Breast Cancer Res Treat 2009;114:579-87.
•Batist G, Gelmon KA, Chi KN, Miller WH, Chia S, et al. Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin Cancer Res 2009;15:692-700.
•Cheang MCU, Chia S, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ and Nielsen TO. Ki67 and HER 2 define poor prognosis luminal B breast cancer. J Natl Cancer Inst 2009 (in press).
•Chia S, Dent S, Ellard S, Ellis PM, Vandenberg T, Gelmon K, Powers J, Walsh W, Seymour L and Eisenhauer EA, et al. Phase II trial of OGX-011 in Combination with Docetaxel in Metastatic Breast Cancer. Clin Cancer Res 2009;15:708-713.
•Chlebowski R, Cuzick J, Amakye D, Bauerfeind I, Buzdar A, Chia S, Cutuli B, Linforth R, Maass N, Noguchi S, robidoux A, Verma S and Hadji P. Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. The Breast 2009;18 (S2):S1-S11.
•Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Mishaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L and Seymour L. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009;27:4536-43.
•Liu S, Chia S, Mehl E, Leung S, Rajput A, Cheang MCU and Nielsen TO. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat 2009 (published online Feb 10, 2009).
•O’Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman D, Bramwell VH, Andrulis I and Prichard KI. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2009 (in press).
•Shaffer R, Tyldesley S, Rolles M, Chia S and Mohamed I. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: A retrospective single institution study. Radiotherapy and Oncology 2009;90:122-126.
•Yerushalmi R, Hayes MM, Gelmon KA, Chia S, Bajdik C, Norris B, Speers C, Hassell P, O’Reilly SE, Allan S and Shenkier TN. A phase II study of neoadjuvant platinum regimen for locally advanced breast cancer: Pathologic response, longer term follow-up and correlation with biomarkers. Clin Breast Cancer 2009;9:166-172.
•